[{"id":"4e4f5de4-fcf1-41a4-925f-4978a391014d","acronym":"TTOS","url":"https://clinicaltrials.gov/study/NCT02344940","created_at":"2021-01-18T11:09:04.966Z","updated_at":"2024-07-02T16:36:55.301Z","phase":"Phase 4","brief_title":"Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer","source_id_and_acronym":"NCT02344940 - TTOS","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • toremifene"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2019-09-24"},{"id":"b664a361-f3d6-454b-ac33-d1ac036b4a77","acronym":"","url":"https://clinicaltrials.gov/study/NCT02506790","created_at":"2021-01-18T12:06:00.828Z","updated_at":"2024-07-02T16:36:56.019Z","phase":"Phase 2","brief_title":"Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer","source_id_and_acronym":"NCT02506790","lead_sponsor":"N.N. Petrov National Medical Research Center of Oncology","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin • toremifene"],"overall_status":"Unknown status","enrollment":" Enrollment 96","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 08/01/2020","primary_completion_date":" 08/01/2020","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2019-09-04"},{"id":"fc5910da-ab73-4042-880e-df20fbdbf62c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03238703","created_at":"2021-01-18T16:00:14.581Z","updated_at":"2024-07-02T16:37:04.362Z","phase":"Phase 4","brief_title":"Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer","source_id_and_acronym":"NCT03238703","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • toremifene • Soltamox (tamoxifen citrate)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 03/14/2023","primary_completion_date":" 03/14/2023","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2018-12-27"}]